📇 Rhumatologue · POITIERS CEDEX · (86) · Hospitalier
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Plateau technique de référence
Centre hospitalier universitaire (CHU) — équipements et expertise pointus pour les cas complexes
Praticien-chercheur
6 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
124.6 rhumatos / 100 000 hab. — département bien doté
8 publications sur 5 ans
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
5
5 articles ont été cités au moins 5fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
120
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
28
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
5
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Université de Poitiers · Centre Hospitalier Universitaire de Poitiers
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Evolution and factors associated with presenteeism in severe asthma after treatment with biologics
2025ArticleRespiratory Medicine
Respiratory Disorders Associated with Antibody–Drug Conjugates: A Combined Analysis of the French and the WHO Pharmacovigilance Databases
2025ArticleClinical Pharmacology and Therapeutics
Improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study
2023ArticleTherapeutic Advances in Respiratory Disease
Severity and phenotypes of dyspnea in asthma: Impact of comorbidities
2023ArticleRespiratory Medicine
Factors associated with daily life physical activity in patients with asthma
2018ArticleHealth Science Reports
Cigarette smoke alters the ability of human dendritic cells to promote anti-Streptococcus pneumoniae Th17 response
2015ArticleRespiratory Research
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CHU LA MILETRIE
2 R DE LA MILETRIE CS 90577, 86021 POITIERS CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Health science reports · 2018
AbstractBackground and ObjectivesLittle is known about the consequences of asthma on daily life physical activity (DLPA). The aim of this study was to evaluate DLPA and determine its relationship to clinical and functional parameters in patients with asthma.MethodsThis was a single‐center prospective study of DLPA conducted between May 2015 and June 2016 in northern France. Fifty‐one adult patients with asthma and 36 healthy control subjects were enrolled. Four DLPA parameters were assessed for 5 consecutive days with a physical activity monitor: number of steps walked per day (SPD), total energy expenditure (EE, in kcal/day), EE spent in physical activity requiring ≥3 metabolic equivalents (METs), and time (min) spent in activities requiring ≥3 METs. Clinical characteristics, pulmonary function tests, 6‐minute walk test, and four questionnaires (modified Medical Research Council [mMRC] for dyspnea, asthma control test [ACT], quality of life [AQLQ], and hospital anxiety and depression scale [HADS]), were evaluated. Comparisons of DLPA parameters between the two groups were performed using an analysis of covariance adjusted for age, sex, and body mass index (BMI). Relationships between DLPA parameters and patient characteristics were assessed in multivariable linear regression models.ResultsCompared with patients with mild/moderate asthma, those with severe asthma had lower mean (± standard deviation) forced expiratory volume in 1 s (FEV1) (66 ± 24 vs 94 ± 15% predicted, P < 0.001), ACT score (16.7 ± 4.5 vs 19.8 ± 4.2, P = 0.015), and AQLQ score (157 ± 40 vs 184 ± 33, P = 0.012). There were no significant differences between the two groups in SPD (6560 ± 3915 vs 8546 ± 3431; adjusted P = 0.95), EE in physical activity requiring ≥3 METs (620 ± 360 vs 660 ± 140 kcal/day; P = 0.86), time spent in activities requiring EE ≥3 (120 ± 54 vs 121 ± 32 min/day; P = 0.69), or total EE (2606 ± 570 vs 2666 ± 551 kcal/day; P = 0.80). These four DLPA measures showed strong inter‐parameter correlations in patients with asthma (r = 0.37–0.95, all P < 0.01). All four parameters were lower in the patients with asthma group than in the control group: SPD, 7651 ± 3755 vs 11704 ± 4054 (adjusted P < 0.001); EE in activities requiring ≥3 METs, 642 ± 360 vs 852 ± 374 kcal/day (adjusted P = 0.041); time spent in activities requiring ≥3 EE, 120 ± 73 vs 189 ± 85 min (adjusted P = 0.005); and total EE, 2639 ± 555 vs 2746 ± 449 kcal/day (adjusted P = 0.007). In the patients with asthma group, the number of SPD correlated with age, FEV1, mMRC score, 6‐minute walk test distance, and HADS scores, but not with BMI or ACT test score. Using multivariate analysis, the number of SPD was associated with only age, anxiety, and FEV1, whereas total EE was associated with mMRC score and BMI.ConclusionAge, anxiety, and FEV1 were significantly associated with the number of SPD in patients with asthma. Addressing anxiety should be further studied as way to attempt to increase physical activity in patients with asthma.
Therapeutic advances in respiratory disease · 2023
Background: Biological therapies have revolutionized the treatment of severe asthma with type 2 inflammation. Although such treatments are very effective in reducing exacerbation and the dose of oral steroids, little is known about the persistence of symptoms in severe asthma patients treated with biologics. Purpose: We aim to describe asthma control and healthcare consumption of severe asthma patients treated with biologics. Design: The Second Souffle study is a real-life prospective observational study endorsed by the Clinical Research Initiative in Severe Asthma: a Lever for Innovation & Science Network. Methods: Adults with a confirmed diagnosis of severe asthma for at least 12 months’ duration were enrolled in the study. A self-administered questionnaire including the Asthma Control Questionnaire (ACQ), Asthma Quality of Life Questionnaire (AQLQ) and a compliance evaluation test was given to the patients. Healthcare consumption within 12 months prior to enrolment was documented. In patients receiving biologics, doctors indicated whether the patients were biologic responders or non-responders. Results: The characteristics of 431 patients with severe asthma were analysed. Among them, 409 patients (94.9%) presented asthma with type 2 inflammation (T2 high) profile, and 297 (72.6%) patients with a T2 high phenotype were treated with a biologic. Physicians estimated that 88.2% of patients receiving biologics were responders. However, asthma control was only achieved in 25.3% of those patients (ACQ > 0.75). A high proportion of patients (77.8%) identified as responders to biologics were not controlled according to the ACQ score. About 50% of patients continue to use oral corticosteroids either daily (25.2%) or more than three times a year for at least three consecutive days (25.6%). Gastro-oesophageal Reflux Disease (GERD) and Obstructive Sleep Apnoea syndrome (OSA) were identified as independent factors associated with uncontrolled asthma. Conclusion: Although a high proportion of severe asthma patients respond to biologics, only 25.3% have controlled asthma. GERD and OSA are independent factors of uncontrolled asthma.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Clinical pharmacology and therapeutics · 2026 · Journal Article
Mirleau V, Hlavaty A, Jutant EM, Hennegrave F, et al.
Respiratory medicine · 2026 · Journal Article
Subocz J, Stoup T, Giovannelli J, Bourdin A, et al.
Respiratory medicine · 2023 · Journal Article
Bousso A, Chuffart C, Leroy M, Gicquello A, et al.
Therapeutic advances in respiratory disease · 2023 · Observational Study
Guilleminault L, Camus C, Raherison-Semjen C, Capdepon A, et al.
EBioMedicine · 2015 · Journal Article
Pichavant M, Sharan R, Le Rouzic O, Olivier C, et al.
Health science reports · 2018 · Journal Article
Hennegrave F, Le Rouzic O, Fry S, Behal H, et al.
Cigarette smoke alters the ability of human dendritic cells to promote anti-Streptococcus pneumoniae Th17 response
Abstract Background Chronic obstructive pulmonary disease (COPD) is associated with chronic inflammation and impaired immune response to pathogens leading to bacteria-induced exacerbation of the disease. A defect in Th17
Improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study
Background:Biological therapies have revolutionized the treatment of severe asthma with type 2 inflammation. Although such treatments are very effective in reducing exacerbation and the dose of oral steroids, little is k
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).